Cholesterol and APOE genotype interact to influence Alzheimer disease progression.
Author(s): Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR
Affiliation(s): Department of Neurology, Indiana University School of Medicine, Indianapolis, USA. revans1@iupui.edu
Publication date & source: 2004-05-25, Neurology., 62(10):1869-71.
Publication type: Clinical Trial; Comparative Study ; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
In this retrospective analysis of 443 Alzheimer disease (AD) patients from a 30-week tacrine trial, change in Alzheimer's Disease Assessment Scale score from baseline to final value was significantly associated with a total serum cholesterol/APOE genotype interaction. Disease progression in the no-APOE epsilon4 allele/high-cholesterol subgroup was greater than in the normal-cholesterol subgroups with or without epsilon4. Cholesterol levels and APOE genotype may interact to affect AD progression. The results are consistent with preclinical data on cholesterol's effects in AD.
|